Precision Medicine in Osteosarcoma: MATCH Trial and Beyond

Area of Science:

• Oncology
• Genomics
• Precision Medicine

Background:

• Osteosarcoma (OS) is a rare bone malignancy with a poor prognosis upon recurrence, lacking established systemic therapies.
• Next-generation sequencing (NGS) has transformed clinical research by enabling detailed tumor genomic profiling.
• Precision medicine trials (PMTs) leverage genomic data to match patients with targeted therapies.

Purpose of the Study:

• To explore the potential of precision medicine trials (PMTs) for treating relapsed osteosarcoma (OS).
• To highlight the role of next-generation sequencing (NGS) in identifying actionable genomic alterations in OS.
• To discuss the challenges and necessity of a multidisciplinary approach in developing PMTs for OS.

Main Methods:

• Tumor and matched normal tissue sequencing using next-generation sequencing techniques.
• Genomic profiling to identify specific genetic alterations in osteosarcoma.
• Development and implementation of precision medicine trials (PMTs) based on identified genomic targets.

Main Results:

• NGS reveals a complex genomic landscape in OS, offering insights into tumor heterogeneity.
• Genomic profiling enables real-time matching of patients to targeted therapies.
• PMTs are emerging as a promising strategy for refractory OS, though still in early development.

Conclusions:

• Precision medicine, guided by comprehensive genomic profiling, holds significant potential for improving outcomes in relapsed osteosarcoma.
• Addressing challenges like OS rarity and tissue complexity requires a multidisciplinary approach for successful PMT development.
• Targeted therapies informed by genomic data represent a hopeful future for patients with limited treatment options.